Tempest Therapeutics – CAR-T Expansion and TPST-2003 Interim Data in Multiple Myeloma
Summary Tempest Therapeutics reported its year-end 2025 business update, highlighting two key developments: the acquisition of dual-targeting CAR-T assets from Factor Bioscience and positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in relapsed/refractory multiple myeloma. While…
